Vifor Fresenius Medical Care Renal Pharma
11
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
77.8%
-8.7% vs industry average
45%
5 trials in Phase 3/4
43%
3 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus
Role: lead
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Role: lead
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Role: lead
Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
Role: lead
Avacostar - (PASS)
Role: lead
Effect of Ferric Carboxymaltose on Exercise Capacity After Kidney Transplantation
Role: collaborator
PA21 Safety and Efficacy in Adult Chinese Subjects
Role: lead
Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial
Role: lead
Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)
Role: lead
A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia
Role: lead
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
Role: collaborator
All 11 trials loaded